Zydus Lifesciences Limited — Others, 17-04-2025: News Verification

Zydus Lifesciences Limited has confirmed receipt of an order from the United States District Court for the District of Delaware regarding a patent dispute with Astellas Pharma Inc. related to the drug Myrbetriq® (mirabegron). The company is assessing the implications of this order on its operations and any available legal recourse. This development has led to a noticeable impact on the company's stock price, reflecting investor concern. The situation poses potential risks, but the management remains committed to high corporate governance standards and timely disclosures.